ReviewJournal of the American Heart Association2024
Medication Changes After Renal Denervation: Current Evidence and Patient Perspectives.
Review in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Addressing Hypertension Treatment Disparities Via Renal Denervation.Current hypertension reports · 2026Review
- Renal Denervation After USA FDA Approval: An Update from an Interventional Cardiologist's Perspective.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal denervation (RDN) is recognized as an adjunct therapy for hypertension management with a favorable and consistent blood pressure-lowering efficacy and safety profile. Alteration in medication burden is another noteworthy outcome of RDN for clinicians and patients. In this review, we summarized current clinical trials and patient perspectives, focusing on the use of antihypertensive medication (AHM) after RDN. The results of randomized controlled trials demonstrated that patients undergoing RDN exhibited lower blood pressure levels with a similar AHM burden or similar blood pressure levels with fewer AHMs than the sham control group. In studies with follow-ups of ≤6 months, AHM use increased or remained generally consistent in patients undergoing RDN, which may be attributed to the prespecified study process. In studies with follow-ups of >6 months, the blood pressure-lowering efficacy of RDN was consistent with a decreasing or similar AHM burden compared with baseline conditions, except for the 36-month results in the SPYRAL HTN-ON MED (Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications) trial. Huge gaps exist between current evidence on medication changes after RDN and patient expectations, which may be addressed through adequate communication in a shared decision-making process and further improvement of the RDN procedure. Moreover, novel evaluation methodologies for assessing medication burden changes, incorporating adherence to AHMs and modifications in drug classes, may be required to evaluate the impact of RDN on medication usage in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.